USPTO serial 90046915
HELA CENTER FOR GENOMIC & SOCIAL RESEARCH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- GULIANO, ROBERT N
- Law office
- TMEG LAW OFFICE 105 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with HELA CENTER FOR GENOMIC & SOCIAL RESEARCH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Research and development in the field of genetics; research and development in the pharmaceutical and biotechnology fields; research and development of advanced learning technologies and teaching methods; research and development of new products for others; research and development of pharmaceuticals for the treatment of age-related diseases and cancer; research and development of technology in the field of molecular biology; research and development of vaccines and medicines; research and development services in connection with physics; research and development services in the field of antibodies; research in the field of chemistry; research in the field of child and adolescent development; research in the field of hair care; research in the field of genomics; research in the field of molecular biology; research on building construction or city planning; research on food; research on the subject of pharmaceuticals; research services in the field of forensic science, namely, analysis, detection and isolation of biological substances in forensic samples; research services in the field of information and telecommunications technology; research, development, design and upgrading of computer software; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; agrochemical research services; bacteriological research and testing; bacteriological consultation and research; basic and clinical research in the field of respiratory science and medicine; biochemical research; biochemical research and analysis; biochemical research and development; biological research; biological research and analysis; biomedical research services; biotechnology research; chemical research; chemical research and analysis; chemical research services; chemical, biochemical, biological and bacteriological research and analysis; clinical research in the field of molecular medicine; compiling data for research purposes in the field of medical science and medical consultancy; conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmology; conducting clinical trials for others; conducting clinical trials for others in the field of cancer biology; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; cosmetics research; cosmetics research for others; DNA analysis services for scientific research purposes; DNA screening for scientific research purposes; Drug, alcohol and DNA screening for forensic research purposes; forensic analysis of surveillance video for forensic research purposes; genetic testing for scientific research purposes; genetic testing of laboratory animals for research purposes; industrial research in the field of molecular medicine; industrial research in the field of genomics; industrial research in the field of genetics; industrial research in the field of microbiology; integrated scientific research on vermin for greenhouses and harvest crops; laboratory research in the field of cancer biology; laboratory research services relating to pharmaceuticals; medical research; medical research services; medical research services in the field of cancer; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research in the field of medical imaging; medical and scientific research in the field of genetics; medical and scientific research in the field of genomics; medical and scientific research in the field of molecular medicine; medical and scientific research in the field of immunology; medical and scientific research in the field of virology; medical and scientific research information in the field of genomics; monitoring of genomic sequencing data for scientific research purposes; pharmaceutical research and development; pharmaceutical research services; product research; product research and development; providing a website featuring educational information in the field of clinical research; providing an on-line searchable database in the field of genetics for scientific research purposes; providing information in the field of plant genetics research resources; providing information on the subject of scientific research in the field of biochemistry and biotechnology; providing laboratory research services in the field of gene expression, namely, cancer biology; providing medical research and scientific research information in the field of oncology via the Internet; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; providing medical testing services and information in the field of cancer research and disease classification; providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto; scientific research; scientific research and development; scientific research consulting in the field of cosmetics; scientific research consulting in the field of pharmacology; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of genetics and genetic engineering; scientific research in the field of immunology; scientific research information in the field of wildlife preservation; scientific and technological services, namely, genome amplification in the field of molecular medicine; scientific consulting and research services relating to foods and dietary supplements; scientific study and research in the field of reproduction, husbandry, and general health of animals; scientific study and research in the field(s) of African American Health Disparities; stem cell research services; technical consultancy in relation to technical research in the field of food and beverages; technology research in the field of genetics; technology consultation and research in the field of genomics, microbiology; testing, inspection or research of pharmaceuticals, cosmetics or foodstuff; testing, inspection or research on agriculture, livestock breeding or fisheries; testing, inspection, research, or development of pharmaceutical preparations for gene therapy; web-based cardiovascular research and analysis services for scientific purposes; zoological research and consultation | ACTIVE | Jan 24, 2022 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 14, 2022 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 14, 2022 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 31, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 31, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 31, 2022 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 3, 2022 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Mar 3, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 3, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 26, 2022 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Jan 25, 2022 | IUAF | USE AMENDMENT FILED | — |
| Jan 25, 2022 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jan 25, 2022 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Jan 25, 2022 | PETG | PETITION TO REVIVE-GRANTED | — |
| Jan 25, 2022 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Jan 19, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 20, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 18, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 18, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 18, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 19, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 24, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 24, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 4, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 21, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 21, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 21, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 21, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 21, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 21, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 7, 2020 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Aug 6, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 14, 2020 | NWAP | NEW APPLICATION ENTERED | — |